Posted in | News | Medical Optics

Sustained Drug Release Could Ease Treatment of Glaucoma and Other Conditions

Taking eye drops multiple times a day can be difficult for patients to do, and because of blinking and tearing, as little as 1 to 7 percent of the dose is actually absorbed by the eye. Now, researchers led by Daniel Kohane, MD, PhD, director of the Laboratory for Biomaterials and Drug Delivery at Children's Hospital Boston, have developed special contact lenses that can gradually dispense a constant amount of medication to the eye, at adjustable rates. They describe their prototype lens in the July issue of Investigative Ophthalmology and Visual Science.

This is a prototype drug-dispensing contact lens. Credit: Copyright 2009 Association for Research in Vision and Ophthalmology (ARVO).

Although other groups have developed drug-releasing contact lenses, none have been able to achieve a constant, steady release of substantial amounts of drug; typically, a burst of drug is delivered in the first few hours, followed by rapidly dwindling amounts that are too low to be therapeutic. Kohane, collaborator Joseph Ciolino, MD, of the Massachusetts Eye and Ear Infirmary, and colleagues at the Department of Chemical Engineering at the Massachusetts Institute of Technology (MIT) created a two-layer contact lens with an inner drug-bearing biodegradable polymer film known as PLGA. Both PLGA and pHEMA (used for the coating) have been well studied and are already approved for ocular use by the Food and Drug Administration.

In laboratory testing, the prototype lenses dispensed ciprofloxacin (an antibiotic often used in eyedrops) for 30 days, the longest duration for which contact lenses are currently approved by the FDA; in some tests, the lenses continued releasing drug for up to 100 days. The amounts dispensed were sufficient to kill pathogens in a laboratory assay.

Kohane and Ciolino see applications in conditions such as glaucoma and dry-eye which require frequent daily eye drops. They have begun to test the lens in animals and plan to begin human testing as soon as possible. The technology recently won the Life Sciences track in MIT's 100K Entrepreneurship Competition.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.